Cytokinetics rises as Bristol Myers flags 'steady growth' for rival drug
** Heart disease drugmaker Cytokinetics' shares CYTK.O rise 5.7% to $40.17
** Rival Bristol Myers Squibb BMY.N stressed that it expects steady growth of heart drug Camzyos in 2025
** Says it is observing "strong global demand, high persistency and new patients coming on to therapy each week," especially after a recent update to its prescribing information
** The update allows for less frequent monitoring and simplifies treatment process for patients and doctors, J.P. Morgan analysts say
** "We also think the label update bodes well for the overall class and could expand the hypertrophic cardiomyopathy (HCM) market," — brokerage
** CYTK is developing a rival heart drug, aficamten, to treat non-obstructive form of HCM, an inherited condition characterized by thickening of heart muscles
** CYTK is expected to report Q1 results on May 6
** As of last close, CYTK has fallen 14.7% YTD
Related Articles
U.S. 10-Year Treasury Yields Stay High — Here Are Wall Street’s Investment Calls
TradingKey - Earlier this month, the U.S. 10-year Treasury yield shot up more than 70 basis points in just a few days, climbing toward 4.6%. Not long ago, it had briefly fallen below 4%.
Trump vs. Powell: Bullish or Bearish for Bitcoin?
If Trump fails to persuade Powell to cut rates, tight liquidity conditions may persist, potentially dragging Bitcoin back to $75,000. On the other hand, if conditions ease, Bitcoin could rally to retest its previous high of $110,000—or even surpass it..jpg)
Alphabet Inc. (GOOGL) Q1 2025 Earnings Preview: AI Innovations Amid Regulatory Scrutiny
TradingKey - Alphabet Inc. (GOOGL) is scheduled to post Q1 2025 results on April 24, 2025, after market close. Analysts see revenue of $89.22 billion, up 11% from the year ago period, and EPS of $2.01 versus $1.89 for the comparable period a year ago.
